Yale University just cracked one of CAR-T’s biggest limitations. Most FDA-approved CAR-Ts struggle when tumors don’t wave enough “cancer flags.” Low-antigen cancers slip through. But Yale researchers may have found a fix: Intrinsically Disordered Regions (IDRs).
-
In culture dishes, IDR-CAR-Ts showed far stronger killing activity, even against cells with low CD19, CD22, or HER2.
-
In mouse models, FUS-IDR CAR-Ts suppressed both blood cancers and low-HER2 colorectal tumors, with reduced exhaustion markers (PD1, LAG3).
-
IDRs are found in ~50% of human proteins - an untapped toolkit for immune engineering.
Why it matters: CAR-T’s problem has never been promise - it’s persistence. If this approach holds, we’re talking broader reach, longer durability, and a new modular playbook for solid tumors.
Every biotech working in immunotherapy should be watching Yale. The door to low-antigen cancers might finally be opening